[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Li, S., Luk, H.Y., Xia, C., Chen, Z., Chan, P. and Boon, S.S. (2022) Oesophageal Carcinoma: The Prevalence of DNA Tumour Viruses and Therapy. Tumour Virus Research, 13, Article ID: 200231. https://doi.org/10.1016/j.tvr.2021.200231
|
[3]
|
Edgren, G., Adami, H.O., Weiderpass, E. and Nyrén, O. (2013) A Global Assessment of the Oesophageal Adenocarcinoma Epidemic. Gut, 62, 1406-1414. https://doi.org/10.1136/gutjnl-2012-302412
|
[4]
|
Tungekar, A., Mandarthi, S., Mandaviya, P.R., Gadekar, V.P., Tantry, A., Kotian, S., et al. (2018) ESCC ATLAS: A Population Wide Compendium of Biomarkers for Esophageal Squamous Cell Carcinoma. Scientific Reports, 8, Article No. 12715. https://doi.org/10.1038/s41598-018-30579-3
|
[5]
|
Li, J., Xu, J., Zheng, Y., Gao, Y., He, S., Li, H., et al. (2021) Esophageal Cancer: Epidemiology, Risk Factors and Screening. Chinese Journal of Cancer Research, 33, 535-547. https://doi.org/10.21147/j.issn.1000-9604.2021.05.01
|
[6]
|
Triantafyllou, T., Van Der Sluis, P., Skipworth, R. and Wijnhoven, B. (2022) The Implementation of Minimally Invasive Surgery in the Treatment of Esophageal Cancer: A Step Toward Better Outcomes. Oncology and Therapy, 10, 337-349. https://doi.org/10.1007/s40487-022-00206-3
|
[7]
|
Hu, Z.H., Li, R.X., Wang, J.T., Wang, G.J., Deng, X.M., Zhu, T.Y., et al. (2023) Thoracolaparoscopic Esophagectomy for Esophageal Cancer with a Cervical Incision to Extract Specimen. Asian Journal of Surgery, 46, 348-353. https://doi.org/10.1016/j.asjsur.2022.04.073
|
[8]
|
Deana, C., Vetrugno, L., Bignami, E. and Bassi, F. (2021) Peri-Operative Approach to Esophagectomy: A Narrative Review from the Anesthesiological Standpoint. Journal of Thoracic Disease, 13, 6037-6051. https://doi.org/10.21037/jtd-21-940
|
[9]
|
Chela, H.K., Gangu, K., Ertugrul, H., Juboori, A.A., Daglilar, E. and Tahan, V. (2022) The 8th Wonder of the Cancer World: Esophageal Cancer and Inflammation. Diseases, 10, Article 44. https://doi.org/10.3390/diseases10030044
|
[10]
|
Li, B., Shao, H., Gao, L., Li, H., Sheng, H. and Zhu, L. (2022) Nano-Drug Co-Delivery System of Natural Active Ingredients and Chemotherapy Drugs for Cancer Treatment: A Review. Drug Delivery, 29, 2130-2161. https://doi.org/10.1080/10717544.2022.2094498
|
[11]
|
Rosario, R., Cui, W. and Anderson, R.A. (2022) Potential Ovarian Toxicity and Infertility Risk Following Targeted Anti-Cancer Therapies. Reproduction and Fertility, 3, R147-R162. https://doi.org/10.1530/RAF-22-0020
|
[12]
|
Kumar, A.R., Devan, A.R., Nair, B., Vinod, B.S. and Nath, L.R. (2021) Harnessing the Immune System against Cancer: Current Immunotherapy Approaches and Therapeutic Targets. Molecular Biology Reports, 48, 8075-8095. https://doi.org/10.1007/s11033-021-06752-9
|
[13]
|
Norguet, E., Dahan, L. and Seitz, J.F. (2012) Targetting Esophageal and Gastric Cancers with Monoclonal Antibodies. Current Topics in Medicinal Chemistry, 12, 1678-1682. https://doi.org/10.2174/156802612803531360
|
[14]
|
Kono, K., Mimura, K., Fujii, H., Shabbir, A., Yong, W.P. and Jimmy So, A. (2012) Potential Therapeutic Significance of HER-Family in Esophageal Squamous Cell Carcinoma. Annals of Thoracic and Cardiovascular Surgery, 18, 506-513. https://doi.org/10.5761/atcs.ra.12.01995
|
[15]
|
Hong, L., Han, Y. and Brain, L. (2013) Epidermal Growth Factor Receptor: An Important Target in Esophageal Cancer. Expert Opinion on Therapeutic Targets, 17, 1179-1185. https://doi.org/10.1517/14728222.2013.820709
|
[16]
|
Leung, K. (2004) N(Epsilon)-(3-[(131)I]Iodobenzoyl)-Lys(5)-N(Alpha)-Maleimido-Gly(1)-GEEEK-Anti-HER2 Nanobody 5F7GGC. In Molecular Imaging and Contrast Agent Database (MICAD), National Center for Biotechnology Information (US), Bethesda.
|
[17]
|
Liu, G., Chen, T., Ding, Z., Wang, Y., Wei, Y. and Wei, X. (2021) Inhibition of FGF-FGFR and VEGF-VEGFR Signalling in Cancer Treatment. Cell Proliferation, 54, e13009. https://doi.org/10.1111/cpr.13009
|
[18]
|
Folkman, J. (1971) Tumor Angiogenesis: Therapeutic Implications. The New England Journal of Medicine, 285, 1182-1186. https://doi.org/10.1056/NEJM197111182852108
|
[19]
|
Melincovici, C.S., Boşca, A.B., Şuşman, S., Mărginean, M., Mihu, C., Istrate, M., et al. (2018) Vascular Endothelial Growth Factor (VEGF)-Key Factor in Normal and Pathological Angiogenesis. Romanian Journal of Morphology and Embryology, 59, 455-467.
|
[20]
|
Dixelius, J., Makinen, T., Wirzenius, M., Karkkainen, M.J., Wernstedt, C., Alitalo, K., et al. (2003) Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) Heterodimerization with VEGFR-2 in Primary Lymphatic Endothelial Cells Regulates Tyrosine Phos-Phorylation Sites. Journal of Biological Chemistry, 278, 40973-40979. https://doi.org/10.1074/jbc.M304499200
|
[21]
|
Zhou, Y., Zhu, X., Cui, H., Shi, J., Yuan, G., Shi, S., et al. (2021) The Role of the VEGF Family in Coronary Heart Disease. Frontiers in Cardiovascular Medicine, 8, Article 738325. https://doi.org/10.3389/fcvm.2021.738325
|
[22]
|
Faiella, A., Riccardi, F., CartenÌ, G., Chiurazzi, M. and Onofrio, L. (2022) The Emerging Role of C-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target. Journal of Oncology, 2022, Article ID: 5179182. https://doi.org/10.1155/2022/5179182
|
[23]
|
De Castro Junior, G., Segalla, J.G., De Azevedo, S.J., Andrade, C.J., Grabarz, D., De Araújo Lima França, B., et al. (2018) A Randomised Phase II Study of Chemoradiotherapy with or without Nimotuzumab in Locally Advanced Oesophageal Cancer: NICE Trial. European Journal of Cancer, 88, 21-30. https://doi.org/10.1016/j.ejca.2017.10.005
|
[24]
|
Yang, X., Zhai, Y., Bi, N., Zhang, T., Deng, L., Wang, W., et al. (2021) Radio-Therapy Combined with Nimotuzumab for Elderly Esophageal Cancer Patients: A Phase II Clinical Trial. Chinese Journal of Cancer Research, 33, 53-60. https://doi.org/10.21147/j.issn.1000-9604.2021.01.06
|
[25]
|
Ruhstaller, T., Thuss-Patience, P., Hayoz, S., Schacher, S., Knorrenschild, J.R., Schnider, A., et al. (2018) Neoadjuvant Chemotherapy Followed by Chemoradiation and Surgery with and without Cetuximab in Patients with Resectable Esophageal Cancer: A Randomized, Open Label, Phase III Trial (SAKK 75/08). Annals of Oncology, 29, 1386-1393. https://doi.org/10.1093/annonc/mdy105
|
[26]
|
Rades, D., Bartscht, T., Hunold, P., Schmidberger, H., König, L., Debus, J., et al. (2020) Radiochemoth-Erapy with or without Cetuximab for Unresectable Esophageal Cancer: Final Results of a Randomized Phase 2 Trial (LEOPARD-2). Strahlentherapie und Onkologie, 196, 795-804. https://doi.org/10.1007/s00066-020-01646-4
|
[27]
|
Waddell, T., Chau, I., Cunningham, D., Gonzalez, D., Okines, A.F., Okines, C., et al. (2013) Epirubicin, Oxaliplatin, and Capecitabine with or without Panitumumab for Patients with Previously Untreated Advanced Oesophagogastric Cancer (REAL3): A Randomised, Openabel Phase 3 Trial. The Lancet Oncology, 14, 481-489. https://doi.org/10.1016/S1470-2045(13)70096-2
|
[28]
|
Moehler, M., Maderer, A., Thuss-Patience, P.C., Brenner, B., Meiler, J., Ettrich, T.J., et al. (2020) Cisplatin and 5-Fluorouracil with or without Epidermal Growth Factor Receptor Inhibition Panitumum-Ab for Patients with Non-Resectable, Advanced or Metastatic Oesophagealsquamous Cell Cancer: A Prospective, Open-Label, Randomisedphase III AIO/EORTC Trial (POWER). Annals of Oncology, 31, 228-235. https://doi.org/10.1016/j.annonc.2019.10.018
|
[29]
|
Dutton, S.J., Ferry, D.R., Blazeby, J.M., Abbas, H., Dahle-Smith, A., Mansoor, W., et al. (2014) Gefitinib for Oesophageal Cancer Progressing after Chemotherapy (COG): A Phase 3, Multicentre, Doubl-Eblind, Placebo-Controlled Randomised Trial. The Lancet Oncology, 15, 894-904. https://doi.org/10.1016/S1470-2045(14)70024-5
|
[30]
|
Petty, R.D., Dahle-Smith, A., Stevenson, D., Osborne, A., Massie, D., Clark, C., et al. (2017) Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer. Journal of Clinical Oncology, 35, 2279-2287. https://doi.org/10.1200/JCO.2016.70.3934
|
[31]
|
Luo, H., Jiang, W., Ma, L., Chen, P., Fang, M., Ding, L., et al. (2020) Icotinib with Concurrent Radiotherapy vs Radiotherapy Alone in Older Adults with Unresectable Esophageal Squamous Cell Carcinoma: A Phase II Randomized Clinical Trial. JAMA Network Open, 3, e2019440. https://doi.org/10.1001/jamanetworkopen.2020.19440
|
[32]
|
Huang, J., Fan, Q., Lu, P., Ying, J., Ma, C., Liu, W., et al. (2016) Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression Or EGFR Gene Amplification: A Single-Arm, Multicenter Phase 2 Study. Journal of Thoracic Oncology, 11, 910-917. https://doi.org/10.1016/j.jtho.2016.02.020
|
[33]
|
Wang, Z.Q., Wang, D.S., Wang, F.H., Ren, C., Tan, Q. and Li, Y.H. (2021) Recombinant Human Endostatin plus Paclitaxel/Nedaplatin for Recurrent or Metastatic Advanced Esophageal Squamous Cell Carc-Inoma: Aprospective, Single-Arm, Open-Label, Phase II Study. Investigational New Drugs, 39, 516-523. https://doi.org/10.1007/s10637-020-01021-1
|
[34]
|
Hu, Z., Sun, S., Zhao, X., Yu, H., Wu, X., Wang, J., et al. (2022) Rh-Endostatin plus Irinotecan/Cisplatin as Second-Line Therapy for Advanced Esophageal Squamous Cell Carcinoma: An Open-Label, Phase II Study. Oncologist, 27, 253-e312. https://doi.org/10.1093/oncolo/oyab078
|
[35]
|
Yanwei, L., Feng, H., Ren, P., Yue, J., Zhang, W., Tang, P., et al. (2020) Safety and Efficacy of Apatinib Monotherapy for Unresectable, Metastatic Esophageal Cancer: A Single-Arm, Open-Label, Phase II Study. Oncologist, 25, e1464-e1472. https://doi.org/10.1634/theoncologist.2020-0310
|
[36]
|
Horgan, A.M., Darling, G., Wong, R., Guindi, M., Liu, G., Jonker, D.J., et al. (2016) Adjuvant Sunitinib Following Chemoradiotherapy and Surgery for Locally Advanced Esophageal Cancer: A Phase II Trial. Diseases of the Esophagus, 29, 1152-1158. https://doi.org/10.1111/dote.12444
|
[37]
|
Moehler, M., Gepfner-Tuma, I., Maderer, A., Thuss-Patience, P.C., Ruessel, J., Hegewisch-Becker, S., et al. (2016) Sunitinib Added to FOLFIRI versus FOLFIRI in Patients with Chemorefractory Advanced Adenocarcinoma of the Stomach or Lower Esophagus: A Randomized, Placebo-Controlled Phase II AIO Trial with Serum Biomarker Program. BMC Cancer, 16, Article No. 699. https://doi.org/10.1186/s12885-016-2736-9
|
[38]
|
Huang, J., Xiao, J., Fang, W., Lu, P., Fan, Q., Shu, Y., et al. (2021) Anlotinib for Previously Treated Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Double-Blind Randomized Phase 2 Trial. Cancer Medicine, 10, 1681-1689. https://doi.org/10.1002/cam4.3771
|
[39]
|
Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. Lancet, 376, 687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
|
[40]
|
Safran, H.P., Winter, K., Ilson, D.H., Wigle, D., DiPetrillo, T., Haddock, M.G., et al. (2022) Trastuzumab with Trimodality Treatment for Oesophageal Adenocarcinoma with HER2 Overexpression (NRG Oncology/RTOG 1010): A Multicentre, Randomised, Phase 3 Trial. The Lancet Journal, 23, 259-269. https://doi.org/10.1016/S1470-2045(21)00718-X
|
[41]
|
Tabernero, J., Hoff, P.M., Shen, L., Ohtsu, A., Shah, M.A., Cheng, K., et al. (2018) Pertuzumab plus Trast-Uzumab and Chemotherapy for HER2-Positive Metastatic Gastric or Gastro-Oesophageal Junction Cancer (JACOB): Final Analysis of a Double-Blind, Randomised, Placebocontrolled Phase 3 Study. The Lancet Oncology, 19, 1372-1384. https://doi.org/10.1016/S1470-2045(18)30481-9
|
[42]
|
Hecht, J.R., Bang, Y.J., Qin, S.K., Chung, H.C., Xu, J.M., Park, J.O., et al. (2016) Lapatinib in Combination with Capecitabine plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarc-Inoma: TRIO-013/LOGiC—A Randomized Phase III Trial. Journal of Clinical Oncology, 34, 443-451. https://doi.org/10.1200/JCO.2015.62.6598
|
[43]
|
Cunningham, D., Stenning, S.P., Smyth, E.C., Okines, A.F., Allum, W.H., Rowley, S., et al. (2017) Peri-Operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma (UK Medical Research Council ST03): Primary Analysis Results of a Multicentre, Open-Label, Randomised Phase 2-3 Trial. The Lancet Oncology, 18, 357-370. https://doi.org/10.1016/S1470-2045(17)30043-8
|
[44]
|
Wilke, H., Muro, K., Van, Cutsem, E., Oh, S.C., Bodoky, G., Shimada, Y., et al. (2014) Ramucirumab plus Paclitaxel Versus Placebo PLUS Paclitaxel in Patients with Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Doubleblind, Randomised Phase 3 Trial. The Lancet Oncology, 15, 1224-1235. https://doi.org/10.1016/S1470-2045(14)70420-6
|
[45]
|
Xu, R.H., Zhang, Y., Pan, H., Feng, J., Zhang, T., Liu, T., et al. (2021) Efficacy and Safety of Weekly Paclitaxel with or without Ramucirumab as Second-Line Therapy for the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (RAINBOW-Asia): A Randomised, Multicentre, Double-Blind, Phase 3 Trial. The Lancet Gastroenterology and Hepatology, 6, 1015-1024. https://doi.org/10.1016/S2468-1253(21)00313-7
|
[46]
|
Fuchs, C.S., Tomasek, J., Yong, C.J., Dumitru, F., Passalacqua, R., Goswami, C., et al. (2014) Ramucirumab Monotherapy for Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Ade-Nocarcinoma (REGARD): An International, Randomised, Multicentre, Placebo-Controlled, Phase 3 Trial. Lancet, 383, 31-39. https://doi.org/10.1016/S0140-6736(13)61719-5
|
[47]
|
Sun, W., Powell, M., O’Dwyer, P.J., Catalano, P., Ansari, R.H., Benson III, A.B. (2010) Phase II Study of Sorafenib in Combination with Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203. Journal of Clinical Oncology, 28, 2947-2951. https://doi.org/10.1200/JCO.2009.27.7988
|
[48]
|
Janjigian, Y.Y., Vakiani, E., Ku, G.Y., Herrera, J.M., Tang, L.H., Bouvier, N., et al. (2015) Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastr-Oesophageal (GE) Junction Cancer. PLOS ONE, 10, E0134731. https://doi.org/10.1371/journal.pone.0134731
|
[49]
|
Malka, D., François, E., Penault-Llorca, F., Castan, F., Bouché, O., Bennouna, J., et al. (2019) FOLFOX Alone or Combined with Rilotu-Mumab or Panitumumab as First-Line Treatment for Patients with Advanced Gastroesophageal Adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): A Randomised, Open-Label, Three-Arm Phase II Trial. European Journal of Cancer, 115, 97-106. https://doi.org/10.1016/j.ejca.2019.04.020
|
[50]
|
Catenacci, D., Tebbutt, N.C., Davidenko, I., Murad, A.M., Al-Batran, S.E., Ilson, D.H., et al. (2017) Ril-Otumumab plus Epirubicin, Cisplatin, and Capecitabine as First-Line Therapy in Advanced MET-Positive Gastric or Gastro-Oesophageal Junction Cancer (RILOMET-1): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 18, 1467-1482. https://doi.org/10.1016/S1470-2045(17)30566-1
|
[51]
|
Shah, M.A., Cho, J.Y., Tan, I.B., Tebbutt, N.C., Yen, C.J., Kang, A., et al. (2016) A Randomized Phase II Study of FOLFOX with or without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction. Oncologist, 21, 1085-1090. https://doi.org/10.1634/theoncologist.2016-0038
|
[52]
|
Pant, S., Patel, M., Kurkjian, C., Hemphill, B., Flores, M., Thompson, D., et al. (2017) A Phase II Study of the C-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. Cancer Investigation, 35, 463-472. https://doi.org/10.1080/07357907.2017.1337782
|
[53]
|
Kraehenbuehl, L., Weng, C.H., Eghbali, S., Wolchok, J.D. and Merghoub, T. (2022) Enhancing Immunotherapy in Cancer by Targeting Emerging Immunomodulatory Pathways. Nature Reviews Clinical Oncology, 19, 37-50. https://doi.org/10.1038/s41571-021-00552-7
|
[54]
|
Han, Y., Liu, D. and Li, L. (2020) PD-1/PD-L1 Pathway: Current Researches in Cancer. American Journal of Cancer Research, 10, 727-742.
|
[55]
|
De Silva, P., Aiello, M., Gu-Trantien, C., Migliori, E., Willard-Gallo, K. and Solinas, C. (2021) Targeting CTLA-4 in Cancer: Is It the Ideal Companion for PD-1 Blockade Immunotherapy Comb-Inations. International Journal of Cancer, 149, 31-41. https://doi.org/10.1002/ijc.33415
|
[56]
|
Kojima, T., Shah, M.A., Muro, K., Francois, E., Adenis, A., Hsu, C.H., et al. (2020) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab versus Chemotherapy in Advanced Esophageal Cancer. Journal of Clinical Oncology, 38, 4138-4148. https://doi.org/10.1200/JCO.20.01888
|
[57]
|
Sun, J.M., Shen, L., Shah, M.A., Enzinger, P., Adenis, A., Doi, T., et al. (2021) Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. Lancet, 398, 759-771. https://doi.org/10.1016/S0140-6736(21)01234-4
|
[58]
|
Kato, K., Cho, B.C., Takahashi, M., Okada, M., Lin, C.Y., Chin, K., et al. (2019) Nivolumab versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 1506-1517. https://doi.org/10.1016/S1470-2045(19)30626-6
|
[59]
|
Doki, Y., Ajani, J.A., Kato, K., Xu, J., Wyrwicz, L., Motoyama, S., et al. (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. The New England Journal of Medicine, 386, 449-462. https://doi.org/10.1056/NEJMoa2111380
|
[60]
|
Kelly, R.J., Ajani, J.A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., et al. (2021) Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. The New England Journal of Medicine, 384, 1191-1203. https://doi.org/10.1056/NEJMoa2032125
|
[61]
|
Mönig, S., Van Hootegem, S., Chevallay, M. and Wijnhoven, B. (2018) The Role of Surgery in Advanced Disease for Esophageal and Junctional Cancer. Best Practice & Research Clinical Gastroenterology, 36-37, 91-96. https://doi.org/10.1016/j.bpg.2018.11.002
|
[62]
|
Wang, H.Y., Zeng, X., Bai, S.Y., Pu, K., Zheng, Y., Ji, R., et al. (2020) The Safety and Efficacy of Endoscopic Submucosal Dissection for Treating Early Oesophageal Carcinoma: A Meta-Analysis. The Annals of The Royal College of Surgeons of England, 102, 702-711. https://doi.org/10.1308/rcsann.2020.0177
|
[63]
|
Shitara, K., Bang, Y.J., Iwasa, S., Sugimoto, N., Ryu, M.H., Sakai, D., et al. (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer. The New England Journal of Medicine, 382, 2419-2430. https://doi.org/10.1056/NEJMoa2004413
|